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Background: The goal of the present study was to assess the effects of computed tomography (CT)-guided
iodine-125 (125I) seed implantation or gelatin sponge particle (GSP) embolization on patients with giant benign
sacral neurogenic tumors.
Methods: A total of 24 cases with giant sacral neurogenic tumor were performed in a retrospective study between
2000 and 2012. Nineteen cases received surgical resection, and five cases received non-surgical treatment. In
surgical group, patients with type III sacral tumor had received a combined anterior-posterior approach and
patients with type IV were treated with simple anterior approach. In non-surgical group, CT-guided 125I seed
implantation or GSP embolization was applied to occlude vessels. Besides, CT scanning or magnetic resonance
imaging was used to assess the size and development of tumors.
Results: Two of the five patients were treated three times with GSP embolization, one had received GSP
embolization combined with CT-guided 125I seed implantation, one case did not receive any treatment, and one
patient was lost to follow-up. Patients in non-surgical group were followed up for 2–8 years.
Conclusions: Our study suggested that CT-guided 125I seed implantation or GSP embolization treatment is very
useful to slow down the development of giant benign sacral neurogenic tumors.
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Sacral neurogenic tumors, which consist of schwannoma
and neurofibroma, originate from sacral nerves and de-
velop along the neural foramens into inside or outside of
the sacral canal [1]. The inward growth of tumors is
generally restricted because of the limited space of the
sacral canal; however, the outward growth of tumors
may form a giant lump anterior to the sacrum. The
complete resection of the tumor is considered to be an
appropriate choice for a patient with sacral neurogenic* Correspondence: czd856@vip.163.com
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article, unless otherwise stated.tumors [2]. Nevertheless, surgical operation is risky due
to the complex anatomical characteristics of this region,
excessive bleeding during surgery, and the propensity for
local relapse [3].
Conservative treatments such as interventional perfusion
[4], radiofrequency ablation [5], endovascular embolization
techniques, and computed tomography (CT)-guided
Iodine-125 (125I) seed implantation are alternative ap-
proaches for neurogenic tumors. Previous studies have
shown that endovascular embolization techniques have
been widely used in the treatment of various human disor-
ders, such as head and neck tumors [6], skull base tumors
[7], and hypervascular spinal tumors [8]. Embolization
provides an effective treatment for sacral neurogenic tu-
mors by blocking the tumor blood supply and promotingdistributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
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CT-guided 125I seed implantation is also applied in the
treatment of lung cancer [9], prostate cancer [10], spinal
metastasis, and primary paraspinal malignancies [11].
In the present study, endovascular embolization tech-
niques or CT-guided 125I seed implantation was performed
for the patients with giant benign sacral neurogenic tu-
mors to assess the curative effects and outcomes of non-
surgical therapy for sacral neurogenic tumors. Our study
aimed to track the development of tumors and evaluate
the prognosis of patients with giant benign sacral neuro-




In this retrospective study, a total of 24 patients (10 males
and 14 females; aged 21 to 69 years) with giant sacral
neurogenic tumor in Shanghai First People’s Hospital
from 2000 to 2012 were recruited, including 19 cases in
operation group and 5 cases in non-operation group.
There were 10 cases of schwannoma and 14 cases of
neurofibroma. Patients who complain of sciatica, sacro-
coccygeal pain, abnormal urine, perineal pain, or low back
and leg pain were hospitalized, and then imageological
examination showed an enlarged sacral canal. This study
was approved by the ethics committee of our Shanghai
First People’s Hospital.
Treatment protocols
Patients with type III sacral neurogenic tumor received a
combined anterior-posterior approach. The presacral
nerves and vessels were separated, and the tumors in
sacral canal were resected. Patients with type IV were
treated with simple anterior approach. Briefly, the verte-
bral lamina was surgically excised, the sacral canal was
uncovered, and then the sacral nerves were separated
carefully. The postoperative complications contained
poor wound healing, wound infection, sensorimotor im-
pairment, or hemorrhagic shock.
Patients who could not tolerate the resection oper-
ation, radiation, and chemotherapy were treated with
non-surgical treatment and received transcatheter arter-
ial embolization (TAE) or CT-guided 125I seed (Shanghai
GMS Pharmaceutical Co., Ltd, Shanghai, China) im-
plantation. Gelatin sponge particles (GSPs) (diameter,
150–350 μm) were chosen as the materials of TAE. In
order to cut off the blood supply to the entire tumor,
femoral artery was punctured and GSPs were inserted
into artery. The 125I seed implantation was performed
under CT guidance for the patients with unresectable
giant benign sacral neurogenic tumor. After skin disin-
fection, the straight needle was advanced until reaching
the tumor with the patients under conscious sedationand local anesthesia. Before seed implantation, the
tumor volume and 125I seeds dose were evaluated by a
computerized treatment planning system (TPS, Prowess,
version 3.02, SSGI, USA). After a post-planning evalu-
ation, the 125I seeds were implanted with a safe range of
particle concentration and 125I seeds should avoid to im-
plant around the rectum, uterus, prostate, and nerve.
The spacing between each seed pair was 0.5–1 cm. CT
scanning or magnetic resonance imaging (MRI) was
used to evaluate the development of tumors [12].
Karnofsky performance status
The KPS is one of the most used methods to assess the
functional status of patients with cancer [13]. The criter-
ion of KPS index was listed as previous study [14].
Results
Surgical treatment
Totally, 19 patients were treated with surgical operation.
Operation duration ranged from 2 to 5 h, with an aver-
age time of 3 h. Blood loss volume was 500 to 5500 mL,
with an average of 2600 mL. All patients with benign
neurlogical tumors underwent marginal resection, and
patients with malignant neurlogical tumors underwent
extended resection. Eighteen cases underwent marginal
resection of distal S2 never root and kept the unilateral
S1 nerve root as horizontal as possible. Another case
underwent partial sacral resection (PSR) because of a
wide range of S1 invaded by tumors. Negative-pressure
draining was provided post-operation. Internal iliac
artery ligation (IIAL) and temporary blocking of abdom-
inal aorta were performed in four patients to control
hemorrhage during operation. Four cases underwent ab-
dominal aorta balloon block to prevent hemorrhage.
Two cases had complication of cerebrospinal fluid leak-
age and then cured after treatment with the higher end
of the bed and antibiotics. The average period of follow-
up was 47 months (range, 12–98 months). Three patients
with benign neurlogical tumors were found postoperative
recurrence, and two patients disease-freely survived. In
addition, two patients were found partially shrunken
tumor and two patients underwent postoperative radio-
therapy locally relapsed.
Non-surgical treatment
The average age of patients in non-operation group was
45.2 years old (range, 32–55 years old). Three patients
had received non-surgical treatment, including two cases
treated three times with gelfoam embolization and one
case treated with gelfoam embolization and CT-guided
125I seed implantation. In addition, one case with sacral
schwannoma did not get any treatment due to economic
reason; another one with sacral schwannoma was lost to
follow-up. Characteristics of patient with non-surgical
Fig. 1 The X-ray films and computerized tomography (CT) scans of patient A before and after gelatin sponge particles (GSPs) combined with
CT-guided 125I seed (n = 30) implantation treatment. a X-ray film of the pelvis taken in March 2005; b pelvic angiography showing the giant
tumors before sacral in March 2005; c, d the CT scan taken in March 2005; e X-ray film of the pelvis taken in May 2009 after gelatin sponge
particles combined with CT-guided 125I seed (n = 30) implantation; f the CT scan taken in October 2010; g the CT scan taken in September 2011
Table 1 Clinical features of patients received non-surgical treatment







A Male 55 Sacrococcygeal pain Sacral neurofibroma 15 × 14 × 11 19 × 18 × 16 Gelfoam embolization +
implantation of 125I seeds
5 80
B Male 51 Low back pain and
sacrococcygeal pain
Sacral neurofibroma 12 × 10 × 8 13 × 10 × 8 Gelfoam embolization
(3 times)
3 90
C Male 51 Physical examination Sacral schwannoma 12 × 9 × 6 13 × 10 × 6 Gelfoam embolization
(3 times)
2 80
D Female 32 Sacrococcygeal pain Sacral schwannoma 12 × 11 × 9 17 × 12 × 10 No treatment 8 80
E Male 41 Low back and leg pain Sacral schwannoma 8 × 7 × 7 Withdraw Withdraw 4 80
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local recurrence and metastasis for all patients during
the follow-up period. Patients treated with non-surgical
treatment were followed up for 2–8 years and had nor-
mal activity with effort.
Typical cases
Patient A (55 years old, male), with sacrococcygeal pain
and numbness in the left leg over an 8-month period,Fig. 2 The computerized tomography (CT) scans of patient B before and a
thrice of GSPs implantation in July 2011, April 2012, and December 2013, re
scans taken in January 2014was diagnosed with sacral neurofibroma. The MRI
showed that the tumors were circumscribed and ex-
hibited lobulated shape. The primary tumor size was
15 × 14 × 11 cm. The lump was extended to the spinal
channel at the S1 nerve root and superior border of coc-
cyx. Meanwhile, the tumor implicated part of the ilium
in both sides and pushed the intestinal canal in pelvic
(Fig. 1a–d). The surgical operation was canceled because
of his sudden cerebral infarction before surgery. So, thefter gelatin sponge particle (GSPs) implantation. Patient B received
spectively. a, b The CT scans taken in February 2011; c, d: The CT
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125I seeds (n = 30) under CT guidance (Fig. 1e) in May
2009. Five years of follow-up showed that the develop-
ment of tumor (19 × 18 × 16 cm) was slow-growing with
a KPS score of 80 after treatment (Fig. 1f, g).
Patient B (51 years old, male), with low back pain and
sacrococcygeal pain, was diagnosed with sacral neuro-
fibroma. The primary tumor size was 12 × 10 × 8 cm. The
patient had received three times gelfoam embolization in
July 2011, April 2012, and December 2013, respectively.
Three years of follow-up indicated that the development
of tumor (13 × 10 × 8 cm) was slow-growing after treat-
ment (Fig. 2).
Patient C (51 years old, male), whose sacral lump
were detected during routine physical examination, was
diagnosed as sacral schwannoma with a tumor size of
12 × 9 × 6 cm. Then, the patient had received three
treatments of gelfoam embolization in July 2012, April
2013, and January 2014, respectively. With a 2-year
follow-up, the tumor (13 × 10 × 6 cm) was slowly ag-
gressive (Fig. 3).
Discussion
Sacral tumors were rare pathologies, and the management
of the tumor generated a complex medical problem,
which were usually diagnosed in advanced stages with ex-
tended dimensions involving the surrounding organs and
sacral nerves [15, 16]. An early diagnosis and treatment
were of great help for the survival of patients. However,
the treatment of sacral neurogenic tumors was still con-
troversial. Surgical treatment could obtain a complete sur-
gical resection. Nevertheless, this treatment was always
restricted due to extensive intraoperative blood loss and
serious complications. In the present study, we performed
surgical and non-surgical treatments for patients with sa-
cral neurogenic tumor. Our results showed that there wasFig. 3 The magnetic resonance imaging (MRI) of patient C after gelatin spoa slow development of tumors for patients who received
gelfoam embolization or gelfoam embolization combined
with CT-guided 125I seed implantation and none of pa-
tients suffered a local relapse.
Due to the risks brought by surgical resection, pallia-
tive treatment was considered to be an effective treat-
ment for tumors, such as TAE and radioactive 125I seed
implantation. Butori et al. [17] had reported that pre-
operative uterine artery embolization could reduce blood
loss during surgery and improve the chances of perfor-
ming conservative surgery. Velmahos et al. [18] had ap-
plied angiographic embolization (AE) to the treatment
of patients with abdominal visceral organ injuries or
major pelvic fractures. Their results indicated that AE,
as a reasonable and safety method, was highly effective
in preventing bleeding caused by injuries. Besides, gel-
foam, a safe and temporary water-insoluble hemostatic
agent, was widely used in isolation or as an adjuvant of
other permanent agents to obstruct vessels communi-
cated with tumors [19]. Kwon et al. [20] had reported
that preoperative GSPs or polyvinyl alcohol particles
embolization was effective to reduce intraoperative and
postoperative blood loss in patients with hypervascular
metastasis to long bones. In our study, patients B and C,
who were diagnosed with neurofibroma and schwannoma
respectively, both had received three times gelfoam
embolization. Later follow-up results demonstrated that
the tumors were moving slowly. The tumor sizes were re-
duced after treatment when compared to the primary size.
Thus, our results suggested that gelfoam embolization
could achieve a certain degree of efficacy on prevention of
sacral tumor growth.
Additionally, it had been reported that CT-guided
brachytherapy using 125I seed implantation, as a safe, ef-
fective, and uncomplicated treatment, could reduce the
pain for patients with advanced pancreatic cancer [21].nge particle (GSPs) implantation taken in July 2014
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implantation and gemcitabine plus cisplatin chemo-
therapy was safe and effective for patients with advanced
non-small cell lung cancer. Jiang et al. [23] concluded
that CT-guided 125I seed implantation was a feasible and
safe treatment approach for patients with recurrent head
and neck cancers. In the present study, one case with
giant sacral neurofibroma was treated with CT-guided
125I seed implantation and GSP embolization, and the
results demonstrated the development of tumors were
slow for 5 years following up, which indicated that CT-
guided 125I seed implantation and GSP embolization
were effective treatment strategies.
However, there were some limitations in our study.
Firstly, this retrospective study lack of complete data.
Secondly, all the patients received conservative treat-
ment were benign tumors, so the effects of CT-guided
125I seed implantation or GSPs embolization on malig-
nancy are required to be confirmed in future experi-
ments. Thirdly, due to the lack of patients treated with
CT-guided 125I seed implantation alone, the differences
between 125I seed implantation and GSPs embolization
for treatment of patients were unknown, which is also
needed to be further explored.
Conclusions
In summary, a retrospective study was performed for
patients with giant benign sacral neurogenic tumors to as-
sess the prognosis after gelfoam embolization or gelfoam
embolization combined with CT-guided 125I seed implant-
ation. The results revealed that non-surgical treatment
was an effective method for preventing the progress and
development of giant benign sacral neurogenic tumors.
Therefore, it is worth thinking twice whether the patient
with giant benign sacral neurogenic tumors need to per-
form a surgery.
Highlights
1. Nineteen cases received surgical and five cases
received non-surgical treatment.
2. Two of the five patients were treated thrice with
GSP embolization.
3. GSPs embolization combined with 125I seed
implantation was performed in one case.
4. Conservative treatment could slow down the
development of benign sacral tumors.
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